ORCA THERAPEUTICS
ORCA Therapeutics is a biopharmaceutical company, designs and develops therapeutics for the treatment of cancer using Oncolytic Replication Competent Agents (ORCA). The ORCA agents/oncolytic viruses are derived from naturally occurring viruses and are engineered to selectively destroy cancer cells, while healthy cells are left unharmed.
ORCA THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Life Science Pharmaceutical
Founded:
2005-01-01
Address:
Amsterdam, Noord-Holland, The Netherlands
Country:
The Netherlands
Website Url:
http://www.orca-therapeutics.nl
Total Employee:
1+
Status:
Active
Contact:
+31 02 0444 1826
Total Funding:
6.5 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API WordPress Content Delivery Network Font Awesome Mobile Non Scaleable Content Sitelinks Search Box Yoast WordPress SEO Plugin JsDelivr
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Employees Featured
Investors List
Agentschap NL
Agentschap NL investment in Debt Financing - ORCA Therapeutics
Official Site Inspections
http://www.orca-therapeutics.nl Semrush global rank: 5.22 M Semrush visits lastest month: 1.56 K
- Host name: hosted.by.qweb.net
- IP address: 217.18.64.11
- Location: Netherlands
- Latitude: 52.3824
- Longitude: 4.8995
- Timezone: Europe/Amsterdam
More informations about "ORCA Therapeutics"
Home - ORCA Therapeutics
ORCA aims to significantly improve the lives of prostate cancer patients by developing safe and highly potent oncolytic virus immunotherapies. Learn more ORCA’s lead compound ORCA …See details»
Company - ORCA Therapeutics
ORCA Therapeutics B.V. is a privately-funded biopharmaceutical company designing and developing new oncolytic immunotherapies for treatment of cancer using Oncolytic Replication …See details»
ORCA Therapeutics - Crunchbase Company Profile
ORCA Therapeutics is a biopharmaceutical company, designs and develops therapeutics for the treatment of cancer using Oncolytic Replication Competent Agents (ORCA). The ORCA agents/oncolytic viruses are derived from …See details»
ORCA Therapeutics: Contact Details and Business Profile
ORCA Therapeutics B.V. is a privately-funded biopharmaceutical company designing and developing new oncolytic immunotherapies for treatment of cancer using Oncolytic Replication …See details»
ORCA Therapeutics BV - Drug pipelines, Patents, Clinical trials
Orca Therapeutics – Netherlands-based Orca Therapeutics BV announced that following a review from an Interim Data and Safety Monitoring Board, the company will continue its Phase I/IIa …See details»
Executive Summary - ORCA Therapeutics
ORCA’s lead product ORCA-010 is a new oncolytic adenovirus based on the Company’s proprietary T1 technology. ORCA-010 has up to ten thousand fold higher oncolytic potency as …See details»
ORCA Therapeutics - Overview, News & Similar companies
Mar 8, 2021 Orca Therapeutics to start highest dose in treatment-naïve prostate cancer 'S-HERTOGENBOSCH, Netherlands, March 9, 2021 /PRNewswire/ -- ORCA Therapeutics B.V., …See details»
Orca Therapeutics BV - VentureRadar
Nov 5, 2020 "ORCA Therapeutics B.V., a clinical-stage biopharmaceutical company developing oncolytic viruses to treat solid tumors, is pleased to announce that, upon review of all safety …See details»
ORCA Therapeutics - Company Profile - Tracxn
Oct 30, 2024 ORCA Therapeutics has 779 competitors. ORCA Therapeutics - Provider of virus mediated immunotherapy for cancer. Raised a total funding of $8.58M over 4 rounds from 4 …See details»
ORCA Therapeutics Company Profile - Office Locations ... - Craft
ORCA Therapeutics is a biopharmaceutical company designing and developing immunotherapies for the treatment of cancer using Oncolytic Replication Competent Agents (ORCA). It utilizes …See details»
ORCA Therapeutics B.V: Contact Details and Business Profile
ORCA Therapeutics BV is a biopharmaceutical company developing a pipeline of innovative anticancer therapies based on the highly promising approach of Oncolytic Replication …See details»
ORCA Therapeutics B.V. - DevelopmentAid
Oct 11, 2024 ORCA Therapeutics B.V. — Consulting Organization from the Netherlands, has experience with Horizon 2020 (2014 - 2020), it`s involved in Health, Research sectors Our …See details»
ORCA Therapeutics B.V. to Start Highest Scheduled Dose in Phase …
Mar 9, 2021 ORCA Therapeutics B.V., a clinical-stage biopharmaceutical company developing oncolytic viruses to treat solid tumors, is pleased to announce that, upon review of all safety …See details»
Technology - ORCA Therapeutics
ORCA Therapeutics’ core technology entails the engineering of oncolytic adenoviruses to safe and effective immunotherapy of cancer. ORCA is developing a pipeline of innovative …See details»
ORCA Therapeutics B.V. to Start Repeat-Dosing in Phase 1/2a …
Sep 7, 2021 ORCA Therapeutics B.V.’s two-part Phase I/IIa study is a multi-center, open-label, dose-escalation study of ORCA-010 in treatment-naïve patients with localized prostate cancer: …See details»
ORCA-010 - ORCA Therapeutics
Through the unique combination of these modifications in the ORCA-010 product, a virus has been created that is more effective in killing cancer cells compared to competitor viruses. …See details»
Orca Therapeutics to start highest dose in treatment-naïve …
Mar 9, 2021 ORCA Therapeutics B.V.'s two-part Phase 1/2a study is a multi-center, open-label, dose-escalation study of ORCA-010 in approximately 24 treatment-naïve patients with …See details»
ORCA Therapeutics B.V. to Start Highest Scheduled Dose in Phase …
ORCA Therapeutics B.V., a clinical-stage biopharmaceutical company developing oncolytic viruses to treat solid tumors, is pleased to announce that, upon review of all safety data from …See details»
Pipeline - ORCA Therapeutics
ORCA’s highly potent lead product ORCA-010 is currently being developed for its first-in-man study. In this first indication, ORCA-010 will be locally administered in the prostate. Since …See details»
Orca Therapeutics Announces Positive DSMB Review in Phase 1/2a …
Oct 19, 2020 Orca Therapeutics BV, a clinical-stage biopharmaceutical company developing oncolytic viruses to treat solid tumors, is pleased to announcethat, upon review of all safety …See details»